Edulis Therapeutics

Edulis Therapeutics is a biotechnology company developing a minimally invasive, endoscopic drug delivery system designed to provide localized, sustained therapy for chronic gastrointestinal (GI) conditions, such as inflammatory bowel disease (IBD) and Crohn’s disease. The company's core technology features a bioresorbable polymer matrix implant that is significantly thinner than a grain of rice. Designed to be placed during a routine outpatient endoscopy, this implant facilitates the controlled release of medication directly at the site of disease for up to 12 months. This approach is intended to enhance bioavailability, reduce systemic side effects associated with oral formulations, and potentially decrease the necessity for more invasive interventions such as surgery.

By offering a long-term, autonomous management solution, Edulis aims to improve patient quality of life while reducing costs associated with standard biological therapies and procedural care. The platform is engineered to be doctor-friendly, requiring minimal training for GI clinicians to use alongside a custom insertion tool. In addition to its primary focus on IBD, the company is exploring broader applications of its drug delivery platform, including microbiome engineering, colorectal cancer, and weight loss management, backed by ongoing preclinical development and various industry-recognized research awards.